Siker Kimbung1, Anikó Kovács2, Pär-Ola Bendahl3, Per Malmström4, Mårten Fernö3, Thomas Hatschek5, Ingrid Hedenfalk6. 1. Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Sweden; CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden. 2. Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden. 3. Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Sweden. 4. Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Sweden; Skåne Department of Oncology, Skåne University Hospital, Lund, Sweden. 5. Department of Oncology and Pathology, Karolinska Institutet and Karolinska University Hospital, Sweden. 6. Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Sweden; CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden. Electronic address: Ingrid.Hedenfalk@med.lu.se.
Abstract
BACKGROUND: Predicting any future metastatic site of early-stage breast cancer is important as it significantly influences the prognosis of advanced disease. This study aimed at investigating the potential of claudin-2, over-expressed in breast cancer liver metastases, as a biomarker for predicting liver metastatic propensity in primary breast cancer. METHODS: Claudin-2 expression was analyzed in two independent cohorts. Cohort 1 included 304 women with metastatic breast cancer diagnosed between 2002 and 2007, while cohort 2 included 237 premenopausal women with early-stage node-negative breast cancer diagnosed between 1991 and 1994. Global transcriptional profiling of fine-needle aspirates from metastases was performed, followed by immunohistochemical analyses in archival primary tumor tissue. Associations between claudin-2 expression and relapse site were assessed by univariable and multivariable Cox regression models including conventional prognostic factors. Two-sided statistical tests were used. RESULTS: CLDN2 was significantly up-regulated (P < 0.001) in liver metastases compared to other metastatic sites. Claudin-2 protein was more frequently expressed in primary tumors from patients who subsequently developed liver metastases (P = 0.02) and high expression was associated with a shorter metastasis-free interval (cohort 1, HR = 1.4, 95% CI = 1.0-1.9; cohort 2, HR = 2.2, 95% CI = 1.3-3.5). Specifically, a significantly shorter interval between primary tumor diagnosis and liver-specific recurrence was observed among patients with high levels of claudin-2 expression in the primary tumor (cohort 1, HR = 2.3, 95% CI = 1.3-3.9). CONCLUSION: These results suggest a novel role for claudin-2 as a prognostic biomarker with the ability to predict not only the likelihood of a breast cancer recurrence, but more interestingly, the liver metastatic potential of the primary tumor.
BACKGROUND: Predicting any future metastatic site of early-stage breast cancer is important as it significantly influences the prognosis of advanced disease. This study aimed at investigating the potential of claudin-2, over-expressed in breast cancer liver metastases, as a biomarker for predicting liver metastatic propensity in primary breast cancer. METHODS:Claudin-2 expression was analyzed in two independent cohorts. Cohort 1 included 304 women with metastatic breast cancer diagnosed between 2002 and 2007, while cohort 2 included 237 premenopausal women with early-stage node-negative breast cancer diagnosed between 1991 and 1994. Global transcriptional profiling of fine-needle aspirates from metastases was performed, followed by immunohistochemical analyses in archival primary tumor tissue. Associations between claudin-2 expression and relapse site were assessed by univariable and multivariable Cox regression models including conventional prognostic factors. Two-sided statistical tests were used. RESULTS:CLDN2 was significantly up-regulated (P < 0.001) in liver metastases compared to other metastatic sites. Claudin-2 protein was more frequently expressed in primary tumors from patients who subsequently developed liver metastases (P = 0.02) and high expression was associated with a shorter metastasis-free interval (cohort 1, HR = 1.4, 95% CI = 1.0-1.9; cohort 2, HR = 2.2, 95% CI = 1.3-3.5). Specifically, a significantly shorter interval between primary tumor diagnosis and liver-specific recurrence was observed among patients with high levels of claudin-2 expression in the primary tumor (cohort 1, HR = 2.3, 95% CI = 1.3-3.9). CONCLUSION: These results suggest a novel role for claudin-2 as a prognostic biomarker with the ability to predict not only the likelihood of a breast cancer recurrence, but more interestingly, the liver metastatic potential of the primary tumor.
Authors: George Pentheroudakis; George Fountzilas; Dimitrios Bafaloukos; Vasiliki Koutsoukou; Dimitrios Pectasides; Dimosthenis Skarlos; Epaminondas Samantas; Haralabos P Kalofonos; Helen Gogas; Nicholas Pavlidis Journal: Breast Cancer Res Treat Date: 2005-12-02 Impact factor: 4.872
Authors: T Hatschek; L Carlsson; Z Einbeigi; E Lidbrink; B Linderholm; B Lindh; N Loman; M Malmberg; S Rotstein; M Söderberg; M Sundquist; T M Walz; M Hellström; H Svensson; G Aström; Y Brandberg; J Carstensen; M Fernö; J Bergh Journal: Breast Cancer Res Treat Date: 2011-11-18 Impact factor: 4.872
Authors: Marcel Smid; Yixin Wang; Yi Zhang; Anieta M Sieuwerts; Jack Yu; Jan G M Klijn; John A Foekens; John W M Martens Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: S Eva Singletary; Garrett Walsh; Jean-Nicolas Vauthey; Steven Curley; Raymond Sawaya; Kristin L Weber; Funda Meric; Gabriel N Hortobágyi Journal: Oncologist Date: 2003
Authors: R Largillier; J-M Ferrero; J Doyen; J Barriere; M Namer; V Mari; A Courdi; J M Hannoun-Levi; F Ettore; I Birtwisle-Peyrottes; C Balu-Maestro; P Y Marcy; I Raoust; M Lallement; E Chamorey Journal: Ann Oncol Date: 2008-07-17 Impact factor: 32.976
Authors: P Dhawan; R Ahmad; R Chaturvedi; J J Smith; R Midha; M K Mittal; M Krishnan; X Chen; S Eschrich; T J Yeatman; R C Harris; M K Washington; K T Wilson; R D Beauchamp; A B Singh Journal: Oncogene Date: 2011-03-07 Impact factor: 9.867
Authors: Aleix Prat; Joel S Parker; Olga Karginova; Cheng Fan; Chad Livasy; Jason I Herschkowitz; Xiaping He; Charles M Perou Journal: Breast Cancer Res Date: 2010-09-02 Impact factor: 6.466
Authors: Yoshiko Shimizu; Hideki Furuya; Paulette M Tamashiro; Kayoko Iino; Owen T M Chan; Steve Goodison; Ian Pagano; Kanani Hokutan; Rafael Peres; Lenora W M Loo; Brenda Hernandez; Aung Naing; Clayton D K Chong; Charles J Rosser; Toshihiko Kawamori Journal: Carcinogenesis Date: 2018-01-12 Impact factor: 4.944
Authors: Sébastien Tabariès; Matthew G Annis; Anthoula Lazaris; Stephanie K Petrillo; Jennifer Huxham; Amri Abdellatif; Vincent Palmieri; Jaclyn Chabot; Radia M Johnson; Steven Van Laere; Cornelis Verhoef; Yasmina Hachem; Sara Yumeen; Nicholas Meti; Atilla Omeroglu; Gulbeyaz Altinel; Zu-Hua Gao; Alan S L Yu; Dirk J Grünhagen; Peter Vermeulen; Peter Metrakos; Peter M Siegel Journal: Commun Biol Date: 2021-06-02